In this episode of The Community Check-In, Eugene Rozenblyum, Senior Director of Trade Relations and Enterprise Drug Solutions at Excellus BlueCross BlueShield, explores the world of biosimilars—a category of drugs that has emerged in the last decade, offering potentially lower-cost alternatives to biologics. He addresses common questions about biosimilars, including their availability globally, the involvement of major pharmaceutical companies like Pfizer and Amgen and the existence of patient assistance programs to alleviate cost concerns.